Shots:
- LEO Pharma has entered into an exclusive global license & transfer agreement with BI to commercialize & advance the development of Spevigo (spesolimab)
- As per the deal, LEO Pharma will handle commercialization & further development of Spevigo in exchange for $105.18M (€90M) upfront, along with milestones & tiered royalties; closing expected in H2’25, subject to merger control clearance
- Spevigo is a humanized, selective monoclonal antibody that blocks interleukin-36 receptor activation for the treatment of autoinflammatory diseases such as generalized pustular psoriasis
Ref: Businesswire| Image: Boehringer Ingelheim & LEO Pharma | Press Release
Related News:- Boehringer Ingelheim Enters a ~$573M Deal with Tessellate Bio to Develop Novel Therapies for ALT-positive tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
